

File No. FDC/MA/21/000016
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(FDC Division)

Tele. No.: 011-23236965
Fax No.: 011-23236973

FDA Bhawan, Kotla Road
New Delhi-110002

Dated:

To,

M/s. Inventia Healthcare Ltd.,
A-215, Road No. 30, Wagle Industrial Estate,
Thane.

12 0 APR 2021

Subject: Permission to conduct Phase III clinical trial with the FDC of Dapagliflozin + Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin (5mg + 20mg & 10mg + 20mg) film coated tablets (Vide protocol no. CRPL/CT/20/002, version no. 00, dated: 18.03.2020)-regarding.

Dear Sir,

With reference to your online application submitted in Form CT-21 on dated 19.01.2021 please find enclosed herewith the "permission to conduct clinical trial study of new drug" bearing no. **CT-06-27/2021** under the provision of Drugs and Cosmetics Act and Rules. The permission is subject to the conditions mentioned below.

Kindly acknowledge receipt to this letter and its enclosures.

Yours faithfully,



(Dr. V. G. Somani)
Drugs Controller General (India)

CONDITIONS OF PERMISSION

- I. Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;
- II. Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
 - i. Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be;
 - ii. Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- III. In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- IV. The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

- V. Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- VI. Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- VII. Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- VIII. Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;
- IX. In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- X. Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- XI. In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
- XII. In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
- XIII. The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- XIV. Where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- XV. The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licencing Authority and may be used for test or analysis of any drug for and on behalf of Central Licencing Authority;
- XVI. The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- XVII. The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- XVIII. The formulation intended to be used in the clinical trial study shall be manufactured under GMP conditions using validated procedures.
- XIX. **The results of the BE study should be presented before the committee before initiating the Phase III clinical trial.**

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

Permission no.: CT-06-27/2021

1. The Central Licencing Authority hereby permits **M/s. Inventia Healthcare Ltd., A-215, Road No. 30, Wagle Industrial Estate, Thane.** (Name and full address with contact details of the applicant) to conduct clinical trial of the new drug or investigational new drug as per protocol number (**Vide protocol no. CRPL/CT/20/002, version no. 00, dated: 18.03.2020** in the below mentioned clinical trial sites.
2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].
3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place:

Date:

Annexure: **20 APR 2021**

Central Licencing Authority

Stamp

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug:	Dapagliflozin + Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin (5mg + 20mg & 10mg + 20mg) film coated tablets
Therapeutic class:	Anti-diabetic
Dosage form:	Tablet
Composition:	Each film coated tablets contains: I. Dapagliflozin 5mg Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg II. Dapagliflozin 10mg Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg
Indications:	It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Details of clinical trial site:

Names and address of clinical trial site:	As per annexure- A
Ethics committee details:	As per annexure- A
Name of principal investigator:	As per annexure- A



S. No.	Name of PI	Site Name	Ethics Committee Name, Address & EC registration No
1	Dr. Sanjiv Maheshwari, M.B.B.S., M.D. (General Medicine)	Jawahar Lal Nehru (J.L.N) Medical College, Ajmer, Rajasthan.	Institutional Ethics Committee, Jawahar Lal Nehru Medical College, Kala Bagh, Ajmer-305001, Rajasthan ECR/1156/Inst/RJ/2018
2	Dr. Prabhat Kumar Sharma, M.B.B.S., M.D. (General Medicine)	Maharaja Agrasen Superspeciality Hospital, Jaipur, Rajasthan.	Institutional Ethics Committee, Maharaja Agrasen Superspeciality Hospital, Central Spine, Agrasen Aspatal Marg, Sector 7, Vidyadhar Nagar, Jaipur-302039, Rajasthan, India. ECR/1222/Inst/RJ/2019
3	Dr. Vipul Khandelwal, M.B.B.S., M.D. (Internal Medicine)	Apex Hospitals Private Limited, Jaipur, Rajasthan.	Institutional Ethics Committee, Apex Hospitals Pvt. Ltd., SP-4 & 6, Malviya Industrial Area, Malviya Nagar, Jaipur-302017, Rajasthan ECR/380/Inst/RJ/2013/RR-19
4	Dr. Mohan Kumar Singh, M.B.B.S., M.D. (Internal Medicine)	W Pratiksha Hospital, Gurugram, Haryana.	ECR/1282/Inst/HR/2019
5	Dr. Debasish Chaudhury, M.B.B.S., M.D. (General Medicine)	Lady Hardinge Medical College & SMT SK Hospital, New Delhi.	Ethics Committee For Human Research, Lady Hardinge Medical College & Associated Hospitals Situated at Shivaji Marg, New Delhi-110001, India ECR/435/Inst/DL/2013/RR-20
6	Dr. Raja Bhattacharya, M.B.B.S., M.D. (General Medicine)	Medical College and Hospital, Kolkata, West Bengal.	Institutional Ethics Committee for Human Research Medical College, Kolkata, 88, College Street, Kolkata-700073, West Bengal. ECR/287/Inst/WB/2013/RR-19
7	Dr. Hrishikesh Bora, M.B.B.S., M.D. (Medicine)	Down Town Hospital, Dispur, Assam.	Ethics Committee, Down Town Hospital, Dispur, G.S. Road, Guwahati-781006, Assam. ECR/549/Inst/AS/2014/RR-20
8	Dr. Arindam Naskar, M.B.B.S., M.D. (Medicine)	Calcutta School of Tropical Medicine, Calcutta, West Bengal.	Clinical Research Ethics Committee School of Tropical Medicine, Kolkata School of Tropical Medicine 108, Chitta Ranjan Avenue, Kolkata-700073, West Bengal, India ECR/194/Inst/WB/2013/RR-19
9	Dr. Vijaykumar Shivajirao Patil, M.B.B.S., M.D. (Medicine)	Prakash Institute of Medical Sciences & Research, Urun-Islampur (PIMS&R), Sangali, Maharashtra.	Prakash Medical College Institutional Ethics Committee, Prakash Institute of Medical Sciences & Research, UrunIslampur (PIMS&R), Islampur-Sangali Road, Islampur, Tal-Walwa, DistSangali, Maharashtra-415409. ECR/1052/Inst/MH/2018
10	Dr. Vijaykumar Bhagwan Barge, M.B.B.S., M.D. (Medicine)	Rajarshee Chhatrapati Shahu Maharaj Govt. Medical College and Chhatrapati Pramila Raje General Hospital, Kolhapur, Maharashtra.	Rajarshee Chhatrapati Shahu Maharaj Govt. Medical College and Chhatrapati Pramila Raje General Hospital, Kolhapur Institutional Ethics Committee 2 (RCSMGMCIEC2), Dasara Chowk, Town Hall, Bhausingji Road, Kolhapur- 416002, Maharashtra. ECR/703/Inst/MH/2015/RR-20
11	Dr. Sagar Vivek Redkar, M.B.B.S., M.D. (General Medicine)	Redkar Hospital and Research Centre, Oshalbag, Goa.	Redkar Hospital Institutional Ethics Committee (RHIEC), Redkar Hospital and Research Centre, Mumbai-Goa Highway, Oxelbag, Dhargal, Pernem, Goa-403513, India ECR/902/Inst/GA/2018
12	Dr. Vijaykumar Shivajirao Patil, M.B.B.S., M.D. (General Medicine)	Apple Saraswati Multispeciality Hospital, Kolhapur, Maharashtra.	Apple Saraswati Multispeciality Hospital Kolhapur, Circuit House To Kadamwadi Road, Bhosalewadi, Kolhapur Maharashtra. ECR/1237/Inst/MH/2019

13	Dr. Krishna Madhukar Giri, M.B.B.S., M.D. (Internal Medicine)	Dhadiwal Hospital in coalition with Shreeji Healthcare, Nashik, Maharashtra.	Dhadiwal Hospital in coalition with Shreeji Healthcare, Nashik, Maharashtra ECR/1149/Inst/MH/2018
14	Dr. D. Anil Kumar, M.B.B.S., M.D. (General Medicine)	Gandhi Hospital, Secunderabad, Telangana.	Gandhi Hospital, Secunderabad, Telangana ECR/180/Inst/AP/2013/RR-19
15	Dr. A. Gopal Rao, M.B.B.S., M.D. (General Medicine)	Government Medical College & Government General Hospital (Old RIMS GGH), Srikakulam, Andhra Pradesh	Government Medical College & Government General Hospital (Old RIMS GGH), Srikakulam, Andhra Pradesh ECR/492/Inst/AP/2013/RR-20
16	Dr. Vikas Reddy Maddali, M.B.B.S., M.D. (General Medicine)	Osmania Medical College & General Hospital, Hyderabad, Telangana	Osmania Medical College & General Hospital, Hyderabad, Telangana ECR/300/Inst/AP/2013/RR-19
17	Dr. V.C. Srinivas Reddy, M.B.B.S., M.D. (General Medicine)	King George Hospital, Andhra Medical College, Visakhapatnam, Andhra Pradesh.	King George Hospital, Andhra Medical College, Visakhapatnam, Andhra Pradesh. ECR/197/Inst/KGH/2013/RR-20

Place: New Delhi

Date:

20 APR 2021

Central Licencing Authority

Stamp

Dr. V. G. SOMANI

Drugs Controller General (G. 200)
Dir. General of Health Services
Ministry of Health and Family Welfare
P. U. A. Bhawan, Kirti Road, N. C. C.
New Delhi-110002